Trial: 201708148

A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

Phase

II

Principal Investigator

Picus, Joel

Disease Site

Prostate

Learn more about this study at: clinicaltrials.gov